Research programme: oral biotherapeutics - Intrexon

Drug Profile

Research programme: oral biotherapeutics - Intrexon

Alternative Names: AG015; Antibody-toxin conjugates - Intrexon; Clostridium difficile enteropathy therapeutic - Intrexon; Clostridium difficile-associated enterocolitis therapeutic - Intrexon; Coeliac Disease ActoBiotics™ - ActoGeniX; Coeliac disease therapeutics - Intrexon; IL-10/proinsulin ActoBiotics™; IL-27 - Intrexon; Inflammatory bowel disease ActoBiotics™; Inflammatory bowel disease therapeutics - Intrexon; Interleukin-27 - Intrexon; Lactococcus lactis expressing human interleukin-27; Lactococcus lactis secreting gluten antigens; Lactococcus lactis secreting human interleukin-27; Microbiome ActoBiotics™; Microbiome modulators - Intrexon; Microbiota ActoBiotics™; Microbiota modulators - Intrexon; Peptide-toxin conjugates - Intrexon; Proinsulin/IL-10 ActoBiotic™

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ActoGeniX
  • Developer Intrexon Corporation; Katholieke Universiteit Leuven; National Cancer Institute (USA); Synthetic Biologics
  • Class Antigens; Bacteria; Cytokines; Hormones; Monoclonal antibodies; Peptides; Recombinant proteins
  • Mechanism of Action Bacterial toxin inhibitors; Enzyme replacements; Helper-inducer T-lymphocyte modulators; Immunomodulators; Immunosuppressants; Interleukin 27 replacements; Metagenome modulators; Regulatory T-lymphocyte stimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Coeliac disease; Type 1 diabetes mellitus

Highest Development Phases

  • Preclinical Coeliac disease; Inflammatory bowel diseases; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Research Digestive system disorders; Phenylketonuria
  • No development reported Enterocolitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Enterocolitis in Belgium (PO, Capsule)
  • 29 Aug 2015 Preclinical trials in Type-2 diabetes mellitus in USA (PO) before August 2015
  • 29 Aug 2015 Preclinical trials in Type-1 diabetes mellitus in Belgium (PO) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top